Graduation or Premature Exit? The Fight Over TAVR’s Evidence Mandate

One of the most closely watched elements of CMS’s 2026 proposal concerns whether Medicare should continue requiring evidence collection for TAVR. Ending coverage with evidence development (CED) for symptomatic patients would close a data-collection chapter that began in 2012. Supporters view the change as recognition of a mature evidence base; several professional societies have urged a more cautious transition.

What CED Bought

Under CED, Medicare coverage is linked to participation in an approved study or national registry. For TAVR, national registry data have supported real-world monitoring of outcomes beyond clinical trials. The mechanism is generally intended to support evidence generation while a technology and its indications evolve, with coverage requirements reconsidered as the evidence base matures.

Two Views of the Evidence Threshold

Supporters of the proposal point to the breadth of clinical and real-world evidence accumulated for TAVR and argue that CED has served its intended purpose for symptomatic severe aortic stenosis. Those favoring continued requirements focus on timing: as coverage expands to asymptomatic patients, they argue that consistent data collection remains important for evaluating outcomes in a broader population. The disagreement is therefore less about the value of evidence than about where mandatory evidence development remains necessary.

A Coordinated Society Response

Five leading cardiovascular and surgical societies jointly recommended continuing the CED framework to address existing and emerging clinical questions. Their January 2026 comment also recommended broadening the coverage language from “symptomatic aortic stenosis” to “aortic valve disease” to accommodate potential future indications, maintaining minimum volume requirements, and removing the PCI-volume requirement based on their assessment that it is not a reliable measure of TAVR outcomes. Subsequent comments on the proposed policy have emphasized preserving the multidisciplinary heart team, nationally consistent quality oversight, and robust clinical data collection while modernizing selected requirements.

Why Timing Matters

The proposal reflects a distinction between patient populations. CMS would end CED for symptomatic severe aortic stenosis while retaining it for asymptomatic severe disease, where additional evidence is still being developed. As TAVR is considered for broader and potentially younger populations, attention is shifting toward patient selection, valve durability, reintervention, and lifetime treatment planning. Registry-based data may continue to play an important role in addressing these questions, whether through CED-supported studies, quality measurement, or voluntary participation.

What to Watch

The expected decision around September 13 will show how CMS balances a mature evidence base for symptomatic disease with continued data needs in expanding indications. Key points to watch include whether the final policy ends CED for symptomatic patients, how it treats registry participation and quality oversight, and whether broader “aortic valve disease” language appears in the final coverage framework.

Sources

• Joint society comment letter — AATS, ACC, HFSA, SCAI, and STS, January 14, 2026 (“continuation of the CED paradigm is essential”).
• STS — statement and President Vinay Badhwar; ACC — statement on the proposal; SCAI — statement and President J. Dawn Abbott (member survey and town hall).
• Cardiovascular Business — reporting on the CED debate and society positions on the June 2026 proposal.
• TCTMD — EARLY TAVR (TCT 2024; NEJM) and CMS rationale on the asymptomatic evidence base.
• CMS — Proposed Decision Memo for TAVR (CAG-00430R2), June 15, 2026.

By Steven D. Harrington, MD, MBA, FACS, ABTS, FACC, FACCP